Physician profile
Mark Christopher Roque
NPI 1467802892
$2,858.98
in general payments reported to CMS, 2019-2025
23 companies · $16.48 in 2025
The $16.48 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $742 · 2022: $517 · 2023: $842 · 2024: $742 · 2025: $16.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $642.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $505.02 | 2021-2024 | |
| Pfizer INC. | $248.23 | 2021-2024 | |
| Lilly USA, LLC | $239.70 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $201.32 | 2021-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.00 | 2021-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $128.85 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $98.65 | 2023-2024 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $84.03 | 2022-2023 | |
| Amarin Pharma, INC. | $83.32 | 2021 | |
| Merck Sharp & Dohme LLC | $76.39 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $69.30 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $56.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.33 | 2022 | |
| Exact Sciences Corporation | $30.05 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $24.17 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.88 | 2024 | Pyrukynd |
| Almatica Pharma LLC | $21.22 | 2023 | Gralise |
| Lucid Diagnostics INC. | $19.73 | 2023 | |
| Medtronic, INC. | $18.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.98 | 2023 | |
| Genentech USA, INC. | $16.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Roque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.